|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: SLC35E2B |
Gene summary for SLC35E2B |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | SLC35E2B | Gene ID | 728661 |
| Gene name | solute carrier family 35 member E2B | |
| Gene Alias | SLC35E2 | |
| Cytomap | 1p36.33 | |
| Gene Type | protein-coding | GO ID | GO:0001701 | UniProtAcc | P0CK96 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 728661 | SLC35E2B | HTA11_347_2000001011 | Human | Colorectum | AD | 5.06e-03 | 2.69e-01 | -0.1954 |
| 728661 | SLC35E2B | HTA11_99999971662_82457 | Human | Colorectum | MSS | 2.28e-03 | 3.36e-01 | 0.3859 |
| 728661 | SLC35E2B | A015-C-104 | Human | Colorectum | FAP | 6.97e-04 | 7.86e-02 | -0.1899 |
| 728661 | SLC35E2B | A002-C-016 | Human | Colorectum | FAP | 2.49e-02 | -1.13e-01 | 0.0521 |
| 728661 | SLC35E2B | A002-C-116 | Human | Colorectum | FAP | 1.93e-03 | -1.36e-01 | -0.0452 |
| 728661 | SLC35E2B | LZE8T | Human | Esophagus | ESCC | 6.70e-04 | 5.78e-02 | 0.067 |
| 728661 | SLC35E2B | LZE20T | Human | Esophagus | ESCC | 2.55e-03 | 4.41e-02 | 0.0662 |
| 728661 | SLC35E2B | LZE24T | Human | Esophagus | ESCC | 1.22e-13 | 1.59e-01 | 0.0596 |
| 728661 | SLC35E2B | P1T-E | Human | Esophagus | ESCC | 1.06e-04 | 2.09e-01 | 0.0875 |
| 728661 | SLC35E2B | P2T-E | Human | Esophagus | ESCC | 6.12e-19 | 2.97e-01 | 0.1177 |
| 728661 | SLC35E2B | P4T-E | Human | Esophagus | ESCC | 2.19e-21 | 4.73e-01 | 0.1323 |
| 728661 | SLC35E2B | P8T-E | Human | Esophagus | ESCC | 4.44e-21 | 3.78e-01 | 0.0889 |
| 728661 | SLC35E2B | P9T-E | Human | Esophagus | ESCC | 2.71e-04 | 2.83e-02 | 0.1131 |
| 728661 | SLC35E2B | P10T-E | Human | Esophagus | ESCC | 8.48e-20 | 3.86e-01 | 0.116 |
| 728661 | SLC35E2B | P11T-E | Human | Esophagus | ESCC | 6.09e-04 | 1.94e-01 | 0.1426 |
| 728661 | SLC35E2B | P12T-E | Human | Esophagus | ESCC | 4.20e-12 | 1.05e-01 | 0.1122 |
| 728661 | SLC35E2B | P15T-E | Human | Esophagus | ESCC | 1.49e-14 | 2.08e-01 | 0.1149 |
| 728661 | SLC35E2B | P16T-E | Human | Esophagus | ESCC | 4.88e-10 | 1.08e-01 | 0.1153 |
| 728661 | SLC35E2B | P20T-E | Human | Esophagus | ESCC | 2.50e-09 | 7.87e-02 | 0.1124 |
| 728661 | SLC35E2B | P21T-E | Human | Esophagus | ESCC | 2.19e-17 | 2.01e-01 | 0.1617 |
| Page: 1 2 3 4 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Colorectum (GSE201348) |  | FAP: Familial adenomatous polyposis |
| CRC: Colorectal cancer | ||
| Colorectum (HTA11) |  | AD: Adenomas |
| SER: Sessile serrated lesions | ||
| MSI-H: Microsatellite-high colorectal cancer | ||
| MSS: Microsatellite stable colorectal cancer | ||
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0001701 | Colorectum | AD | in utero embryonic development | 110/3918 | 367/18723 | 2.36e-05 | 4.62e-04 | 110 |
| GO:00017012 | Colorectum | MSS | in utero embryonic development | 99/3467 | 367/18723 | 3.71e-05 | 7.10e-04 | 99 |
| GO:00017013 | Colorectum | FAP | in utero embryonic development | 81/2622 | 367/18723 | 1.58e-05 | 4.10e-04 | 81 |
| GO:000170119 | Esophagus | ESCC | in utero embryonic development | 243/8552 | 367/18723 | 1.00e-15 | 6.86e-14 | 243 |
| GO:000182412 | Esophagus | ESCC | blastocyst development | 73/8552 | 106/18723 | 1.13e-06 | 1.40e-05 | 73 |
| GO:000170116 | Oral cavity | OSCC | in utero embryonic development | 207/7305 | 367/18723 | 7.92e-12 | 2.95e-10 | 207 |
| GO:00018243 | Oral cavity | OSCC | blastocyst development | 66/7305 | 106/18723 | 1.04e-06 | 1.40e-05 | 66 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| SLC35E2B | SNV | Missense_Mutation | novel | c.901C>G | p.Leu301Val | p.L301V | P0CK96 | protein_coding | tolerated(0.15) | benign(0.036) | TCGA-A2-A0CR-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | CR |
| SLC35E2B | SNV | Missense_Mutation | novel | c.771N>T | p.Glu257Asp | p.E257D | P0CK96 | protein_coding | deleterious(0.04) | possibly_damaging(0.794) | TCGA-PL-A8LZ-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | paclitaxel | SD |
| SLC35E2B | insertion | Frame_Shift_Ins | novel | c.654_655insGGTGT | p.Ser219GlyfsTer66 | p.S219Gfs*66 | P0CK96 | protein_coding | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SLC35E2B | insertion | Frame_Shift_Ins | novel | c.653_654insACGCTCAGCAGTGTGTCTCGCT | p.Ser219ArgfsTer207 | p.S219Rfs*207 | P0CK96 | protein_coding | TCGA-A8-A06Q-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD | ||
| SLC35E2B | insertion | Frame_Shift_Ins | novel | c.717_718insCC | p.Val240ProfsTer44 | p.V240Pfs*44 | P0CK96 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| SLC35E2B | insertion | In_Frame_Ins | novel | c.716_717insGGGTCTCCTGCTGCCACGGTGGGCACTCAGAACTTC | p.Asn239delinsLysGlyLeuLeuLeuProArgTrpAlaLeuArgThrSer | p.N239delinsKGLLLPRWALRTS | P0CK96 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| SLC35E2B | SNV | Missense_Mutation | novel | c.725N>T | p.Ser242Leu | p.S242L | P0CK96 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-DS-A7WH-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| SLC35E2B | SNV | Missense_Mutation | rs756610571 | c.521C>T | p.Thr174Met | p.T174M | P0CK96 | protein_coding | deleterious(0) | probably_damaging(0.996) | TCGA-ZJ-AB0H-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Unknown | Unknown | SD |
| SLC35E2B | SNV | Missense_Mutation | rs762246071 | c.835N>T | p.Asp279Tyr | p.D279Y | P0CK96 | protein_coding | deleterious(0.01) | probably_damaging(0.984) | TCGA-A6-5667-01 | Colorectum | colon adenocarcinoma | Female | <65 | III/IV | Chemotherapy | oxaliplatin | SD |
| SLC35E2B | SNV | Missense_Mutation | rs778277949 | c.938N>T | p.Thr313Met | p.T313M | P0CK96 | protein_coding | deleterious(0.02) | probably_damaging(0.995) | TCGA-A6-6653-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |